5323722026-04-012026-06-305323722026-06-305323722026-04-012026-06-30in-capmkt:OtherExpenses1Member5323722026-04-012026-06-30in-capmkt:ReportableSegments1Member5323722026-04-012026-06-30in-capmkt:ReportableSegments2Member5323722026-04-012026-06-30in-capmkt:ReportableSegments3Member5323722026-04-012026-06-30in-capmkt:ReportableSegments4Member5323722026-04-012026-06-30in-capmkt:ReportableSegments5Member5323722026-04-012026-06-30in-capmkt:ReportableSegments1Member5323722026-04-012026-06-30in-capmkt:ReportableSegments2Member5323722026-04-012026-06-30in-capmkt:ReportableSegments3Member5323722026-04-012026-06-30in-capmkt:ReportableSegments4Member5323722026-04-012026-06-30in-capmkt:ReportableSegments5Member5323722026-04-012026-06-30in-capmkt:ReportableSegments1Member5323722026-06-30in-capmkt:ReportableSegments1Member5323722026-04-012026-06-30in-capmkt:ReportableSegments2Member5323722026-06-30in-capmkt:ReportableSegments2Member5323722026-04-012026-06-30in-capmkt:ReportableSegments3Member5323722026-06-30in-capmkt:ReportableSegments3Member5323722026-04-012026-06-30in-capmkt:ReportableSegments4Member5323722026-06-30in-capmkt:ReportableSegments4Member5323722026-04-012026-06-30in-capmkt:ReportableSegments5Member5323722026-06-30in-capmkt:ReportableSegments5Member5323722026-04-012026-06-30in-capmkt:ReportableSegments1Member5323722026-06-30in-capmkt:ReportableSegments1Member5323722026-04-012026-06-30in-capmkt:ReportableSegments2Member5323722026-06-30in-capmkt:ReportableSegments2Member5323722026-04-012026-06-30in-capmkt:ReportableSegments3Member5323722026-06-30in-capmkt:ReportableSegments3Member5323722026-04-012026-06-30in-capmkt:ReportableSegments4Member5323722026-06-30in-capmkt:ReportableSegments4Member5323722026-04-012026-06-30in-capmkt:ReportableSegments5Member5323722026-06-30in-capmkt:ReportableSegments5Member5323722026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532372VIRINCHINOTLISTEDINE539B01017VIRINCHI LIMITEDMain BoardEquity2026-04-012027-03-312026-08-132026-08-07INRLakhsQuarterlyFirst quarterMulti segment2026-08-1319:00:002026-08-1319:30:00Declaration of unmodified opinion2026-04-012026-06-30UnauditedConsolidated701342000584000701926000039461000-255200023848900078880000134887000277131000766296000-643700000-6437000014777000-58187000-434100000-209600000002579200048320000483200000001127074000100.040.04000.040.041. The above Un-Audited Financial Results for the 1st Quarter ended on June 30, 2026, were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 13, 2026. <br /> <br /> 2. The figures for the quarter ended March 31, 2026 are the balancing figure between the audited figures of the full financial year and the published year-to-date figures upto the 3rd quarter of respective financial years which were subject to Limited Review by the Statutory Auditor of the Company. <br /> <br /> 3. The Audited Financial Results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of Companies Act, 2013 ('The Act') read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <br /> <br /> 4. The Consolidated Results include results of all subsidiaries including the main contributing subsidiary companies, viz., Virinchi Health Care Private Limited, KSoft Systems Inc. <br /> <br /> 5. The Company has Thirteen(13) subsidiaries, viz., Virinchi Health Care Private Limited, Tyohar Foods Private Limited, Qfund Technologies Private Limited, Virinchi Learning Private Limited, Virinchi Media And Entertainment Private Limited, Tensor Fields Consultancy Services Private Limited, Virinchi Combinatorics And Systems Biology Private Limited, Virinchi Infra And Realty Private Limited, V23 Medical Solutions Private Limited, Virinchi Capital Private Limited, Asclepius Consulting & Technologies Private Limited, Ksoft Systems Inc (USA) & Virinchi Technologies Limited (Canada) and has no associate / joint venture companies as on March 31, 2026. <br /> <br /> 6. The Company and its subsidiaries operate in 4 major Segments Viz., SaaS Business (US Fintech), IDC & IT Services, Health Care Services and Payment & Credit Services (India Fintech). <br /> <br /> 7. The Company has allotted 39,10,476 equity shares pursuant to conversion of warrants issued on preferential basis during the quarter ended June 30, 2026. <br /> <br /> 8. The above financial results are available on the stock exchange website www.bseindia.com , www.nseindia.com and company’s website www.virinchi.com. <br /> <br /> 9. Previous year’s/period’s figures are rearranged/ regrouped wherever necessary <br /> Administrative Expenditure277131000SAAS Business411850000IDC & IT Services105731000Health Care Services171053000IT Enabled Services12708000Payment & Credit Services07013420000701342000SAAS Business96640000IDC & IT Services5287000Health Care Services-79757000IT Enabled Services1271000Payment & Credit Services-95160001392500078880000-584000-64371000SAAS Business0IDC & IT Services0Health Care Services0IT Enabled Services0Payment & Credit Services0000SAAS Business0IDC & IT Services0Health Care Services0IT Enabled Services0Payment & Credit Services0000UnauditedtrueP MURALI & COtrue2028-11-30